A J Busti

Summary

Affiliation: Texas Tech University Health Sciences Center
Country: USA

Publications

  1. ncbi Atazanavir for the treatment of human immunodeficiency virus infection
    Anthony J Busti
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, Dallas Ft Worth Regional Campus, Dallas, Texas, USA
    Pharmacotherapy 24:1732-47. 2004
  2. ncbi Tegaserod-induced myocardial infarction: case report and hypothesis
    Anthony J Busti
    School of Pharmacy Dallas Ft Worth Regional Campus, Texas Tech University Health Sciences Center, Dallas, Texas 75216, USA
    Pharmacotherapy 24:526-31. 2004
  3. ncbi A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients
    A J Busti
    Texas Tech University Health Sciences Center School of Pharmacy, Dallas Ft Worth Regional Campus, Dallas, TX 75216, USA
    HIV Med 7:317-22. 2006
  4. doi Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin
    Anthony J Busti
    School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX 75216, USA
    J Cardiovasc Pharmacol 51:605-10. 2008
  5. ncbi Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing
    Anthony J Busti
    Texas Tech University Health Sciences Center School of Pharmacy, Dallas Ft Worth Regional Campus, Dallas, Texas 75216, USA
    Pharmacotherapy 25:1566-91. 2005
  6. ncbi The role of oral direct thrombin inhibitors in the treatment of venous thromboembolism
    Anthony J Busti
    School of Pharmacy, Texas Tech University Health Sciences Center, Dallas Veterans Affairs Medical Center, Dallas, Texas 75216, USA
    Pharmacotherapy 24:184S-189S. 2004
  7. doi Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus
    Sean T Nguyen
    Texas Tech University Health Sciences Center School of Pharmacy, Dallas Fort Worth Regional Campus, Dallas, Texas 75216, USA
    Pharmacotherapy 28:323-30. 2008
  8. pmc Multicenter evaluation of vancomycin dosing: emphasis on obesity
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
    Am J Med 121:515-8. 2008
  9. doi A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature
    Amy M Bain
    School of Pharmacy, Texas Tech University Health Sciences Center, Dallas Forth Worth Regional Campus, Dallas, Texas 75216, USA
    Pharmacotherapy 28:932-8. 2008
  10. doi Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir
    Anthony J Busti
    Texas Tech University Health Sciences Center School of Pharmacy, Dallas, Texas, USA
    J Investig Med 56:539-44. 2008

Collaborators

Detail Information

Publications16

  1. ncbi Atazanavir for the treatment of human immunodeficiency virus infection
    Anthony J Busti
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, Dallas Ft Worth Regional Campus, Dallas, Texas, USA
    Pharmacotherapy 24:1732-47. 2004
    ..We conclude that atazanavir is a distinctively characteristic protease inhibitor owing to its in vitro potency, once-daily dosing, distinct initial resistance pattern, and infrequent association with metabolic abnormalities...
  2. ncbi Tegaserod-induced myocardial infarction: case report and hypothesis
    Anthony J Busti
    School of Pharmacy Dallas Ft Worth Regional Campus, Texas Tech University Health Sciences Center, Dallas, Texas 75216, USA
    Pharmacotherapy 24:526-31. 2004
    ..When considering prescribing a drug with 5-HT1 receptor agonist activity, clinicians should review the patient's medical history specifically for the presence of underlying cardiovascular risk factors...
  3. ncbi A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients
    A J Busti
    Texas Tech University Health Sciences Center School of Pharmacy, Dallas Ft Worth Regional Campus, Dallas, TX 75216, USA
    HIV Med 7:317-22. 2006
    ....
  4. doi Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin
    Anthony J Busti
    School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX 75216, USA
    J Cardiovasc Pharmacol 51:605-10. 2008
    ..The objective is to study the pharmacokinetic interaction of RSV with atazanavir/ritonavir (ATV/RTV) or fosamprenavir/ritonavir (FPV/RTV)...
  5. ncbi Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing
    Anthony J Busti
    Texas Tech University Health Sciences Center School of Pharmacy, Dallas Ft Worth Regional Campus, Dallas, Texas 75216, USA
    Pharmacotherapy 25:1566-91. 2005
    ..Clinicians must carefully evaluate individual patient risk factors, disease severity, and the pharmacokinetics of available therapies when weighing the risks and benefits of discontinuing therapy in the perioperative setting...
  6. ncbi The role of oral direct thrombin inhibitors in the treatment of venous thromboembolism
    Anthony J Busti
    School of Pharmacy, Texas Tech University Health Sciences Center, Dallas Veterans Affairs Medical Center, Dallas, Texas 75216, USA
    Pharmacotherapy 24:184S-189S. 2004
    ..Although there is more to learn about ximelagatran, available data suggest that it is likely to be the most significant therapeutic advance in this area in over 50 years...
  7. doi Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus
    Sean T Nguyen
    Texas Tech University Health Sciences Center School of Pharmacy, Dallas Fort Worth Regional Campus, Dallas, Texas 75216, USA
    Pharmacotherapy 28:323-30. 2008
    ....
  8. pmc Multicenter evaluation of vancomycin dosing: emphasis on obesity
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
    Am J Med 121:515-8. 2008
    ..There is a paucity of data available regarding the dosing of antimicrobials in obesity. However, data are available demonstrating that vancomycin should be dosed on the basis of actual body weight...
  9. doi A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature
    Amy M Bain
    School of Pharmacy, Texas Tech University Health Sciences Center, Dallas Forth Worth Regional Campus, Dallas, Texas 75216, USA
    Pharmacotherapy 28:932-8. 2008
    ....
  10. doi Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir
    Anthony J Busti
    Texas Tech University Health Sciences Center School of Pharmacy, Dallas, Texas, USA
    J Investig Med 56:539-44. 2008
    ..However, its effects on insulin sensitivity have not been elucidated. We conducted this study to test the hypothesis that ATV improves insulin resistance and dyslipidemia...
  11. doi Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy
    Anita P Rahman
    School of Pharmacy, Texas Tech University Health Sciences Center, Dallas Fort Worth Regional Campus, Dallas, Texas 75216, USA
    Pharmacotherapy 28:913-9. 2008
    ....
  12. ncbi Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk
    Stephen P Motsko
    University of Texas at Austin School of Pharmacy, Austin, Texas, USA
    Drug Saf 29:621-32. 2006
    ..e. etodolac, nabumetone and salsalate), and selective COX-2 inhibitors...
  13. ncbi Additional antiretroviral and immunosuppressive drug-drug interactions
    Anthony J Busti
    Kidney Int 66:2469; author reply 2469. 2004
  14. ncbi Reteplase in acute myocardial infarction
    Anthony J Busti
    JAMA 291:2429-30; author reply 2430. 2004
  15. ncbi Ranolazine as add-on therapy for patients with severe chronic angina
    Justin S Hooper
    JAMA 291:1959; author reply 1959-60. 2004
  16. ncbi Prednisone for chronic obstructive pulmonary disease
    Anthony J Busti
    N Engl J Med 349:1288-90; author reply 1288-90. 2003